Companies › TG Therapeutics
2 active drug programs in 12 registered trials: 7 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Neurology, Immunology, Oncology, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ublituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Multiple Sclerosis; Myasthenia Gravis … | Jan 2027 |
| Azercabtagene zapreleucel (azer-cel) CAR-T cell therapy targeting CD19-expressing B cells | CD19 | Phase 1 | B-cell Mediated Autoimmune Disorders | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06680037 | Azercabtagene zapreleucel (azer-cel) | Phase 1 | B-cell Mediated Autoimmune Disorders | Neurology | Dec 2026 |
| NCT05877963 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis | Neurology | Jan 2027 |
| NCT04783415 | Ublituximab | Phase 2 | Mantle Cell Lymphoma | Oncology | Jul 2027 |
| NCT07503873 | Ublituximab | Phase 2 | Multiple Sclerosis | Neurology | Jul 2027 |
| NCT04624633 | Ublituximab | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Jan 2028 |
| NCT07673744 | Ublituximab | Phase 2 | Myasthenia Gravis | Neurology | Jul 2028 |
| NCT07103746 | Ublituximab | Phase 2 | Autoimmune Disorders | Immunology | Aug 2028 |
| NCT07680946 | Ublituximab | Phase 2 | Schizophrenia | Psychiatry | Dec 2028 |
| NCT07211633 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis | Neurology | Dec 2028 |
| NCT07225361 | Ublituximab | Phase 4 | Multiple Sclerosis | Neurology | Mar 2029 |
| NCT07220252 | Ublituximab | Phase 2 | Relapsing Multiple Sclerosis | Neurology | Jan 2030 |
| NCT04130997 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis (RMS) | Neurology | May 2032 |
Cash and short-term investments of $557m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Roche Bristol-Myers Squibb Gilead Sciences Chongqing Precision Biotech AstraZeneca ImmunityBio Amgen Allogene Therapeutics Miltenyi Biomedicine Biocad
Autolus Aurinia Pharmaceuticals Sarepta Therapeutics MeiraGTx Biogen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.